Relapsed or Refractory Myelodysplastic Syndromes (R/R MDS) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034

 Relapsed or Refractory Myelodysplastic Syndromes (R/R MDS) Market Outlook

Thelansis’s “Relapsed or Refractory Myelodysplastic Syndromes (R/R MDS) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Relapsed or Refractory Myelodysplastic Syndromes (R/R MDS) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Relapsed or Refractory Myelodysplastic Syndromes (R/R MDS) Overview

Myelodysplastic syndromes (MDS) are characterized by ineffective hematopoiesis leading to reduced blood cell production and clonal instability, which carries a potential risk of progressing to acute myeloid leukemia (AML). Individuals affected by MDS experience a significant burden of symptoms and are also susceptible to mortality due to complications arising from reduced blood cell counts and the development of AML. The etiology of MDS is currently understood in only 15% of cases. Inherited susceptibility to MDS is observed in approximately one-third of pediatric MDS cases, encompassing conditions such as Down syndrome, Fanconi anemia, and neurofibromatosis. While less common in adults, an inherited predisposition should be considered when MDS arises in young adults or families with a history of MDS, AML, or aplastic anemia. Familial instances of MDS have been associated with point mutations in various genes, including DDX41, GATA2, RUNX1, ANKRD26, ETV6, and genes related to the telomerase complex (TERC and TERT). Environmental factors contributing to MDS include prior exposure to chemotherapeutic agents, particularly alkylating agents, and purine analogs, as well as radiotherapy or ionizing radiation and tobacco use. Noteworthy occupational factors encompass benzene and its derivatives, with a heightened incidence of MDS among agricultural and industrial workers. Diagnosing MDS involves assessing blood and bone marrow samples, revealing reduced blood cell counts and typically hypercellular (though sometimes hypocellular) marrow displaying dysplastic features, possibly accompanied by an excess of immature cells (blasts). Patients grappling with relapsed or refractory higher-risk myelodysplastic syndromes have a discouraging median overall survival ranging from 4.3 to 5.6 months, along with a 28% one-year survival probability following the failure of the two endorsed hypomethylating agents, namely azacitidine (Aza) and decitabine (Dec).

 

Geography coverage:

G8 (United States, EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)

Insights driven by robust research, including:

• In-depth interviews with leading KOLs and payers
• Physician surveys
• RWE analysis for claims and EHR datasets
• Secondary research (e.g., peer-reviewed journal articles, third-party research databases)

Deliverables format and updates*:

• Detailed Report (PDF)
• Market Forecast Model (MS Excel-based automated dashboard)
• Epidemiology (MS Excel; interactive tool)
• Executive Insights (PowerPoint presentation)
• Others: regular updates, customizations, consultant support

*As per Thelansis’s policy, we ensure that we include all the recent updates before releasing the report content and market model.

Salient features of Market Forecast model:

• 10-year market forecast (2024–2034)
• Bottom-up patient-based market forecasts validated through the top-down sales methodology
• Covers clinically and commercially-relevant patient populations/ line of therapies
• Annualized drug-level sales and patient share projections
• Utilizes our proprietary Epilansis and Analog tool (e.g., drug uptake and erosion) datasets and conjoint analysis approach
• Detailed methodology/sources & assumptions
• Graphical and tabular outputs
• Users can customize the model based on requirements

Key business questions answered:

• How can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)?
• How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments?
• What is the 10-year market outlook for sales and patient share?
• Which events will have the greatest impact on the market’s trajectory?
• What insights do interviewed experts provide on current and emerging treatments?
• Which pipeline products show the most promise, and what is their potential for launch and future positioning?
• What are the key unmet needs and KOL expectations for target profiles?
• What key regulatory and payer requirements must be met to secure drug approval and favorable market access?
• and more…

Read more: Relapsed or Refractory Myelodysplastic Syndromes (R/R MDS) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034